biote (BTMD) Stock Overview
Operates in practice-building business within the hormone optimization space. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BTMD Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
biote Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.77 |
| 52 Week High | US$6.36 |
| 52 Week Low | US$2.32 |
| Beta | 1.16 |
| 1 Month Change | 9.49% |
| 3 Month Change | -6.73% |
| 1 Year Change | -53.52% |
| 3 Year Change | -29.16% |
| 5 Year Change | n/a |
| Change since IPO | -72.44% |
Recent News & Updates
Restructuring At Biote Will Drive Greater Growth And Profitability
Sep 10Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09
Recent updates
Restructuring At Biote Will Drive Greater Growth And Profitability
Sep 10Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09Benign Growth For biote Corp. (NASDAQ:BTMD) Underpins Stock's 28% Plummet
Aug 08biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 10Market Participants Recognise biote Corp.'s (NASDAQ:BTMD) Earnings
May 09biote Corp. (NASDAQ:BTMD) Soars 26% But It's A Story Of Risk Vs Reward
Dec 02Market Cool On biote Corp.'s (NASDAQ:BTMD) Revenues
Sep 27
Biote's Innovative Strategies And Expansions Set To Enhance Revenue And Shareholder Value
Expanding the practitioner network and launching BioteRx aim to uniquely position the company in the wellness market, possibly boosting revenue through differentiated service offerings.biote initiated as a buy at Truist on leadership in hormone optimization; sees 138% upside
Sep 27Biote partners with IMAC Holdings
Sep 07Shareholder Returns
| BTMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.5% | 1.4% | 2.6% |
| 1Y | -53.5% | 24.2% | 14.2% |
Return vs Industry: BTMD underperformed the US Pharmaceuticals industry which returned 24.2% over the past year.
Return vs Market: BTMD underperformed the US Market which returned 14.2% over the past year.
Price Volatility
| BTMD volatility | |
|---|---|
| BTMD Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BTMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BTMD's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 217 | Bret Christensen | www.biote.com |
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
biote Corp. Fundamentals Summary
| BTMD fundamental statistics | |
|---|---|
| Market cap | US$124.61m |
| Earnings (TTM) | US$28.79m |
| Revenue (TTM) | US$195.65m |
Is BTMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTMD income statement (TTM) | |
|---|---|
| Revenue | US$195.65m |
| Cost of Revenue | US$54.06m |
| Gross Profit | US$141.58m |
| Other Expenses | US$112.79m |
| Earnings | US$28.79m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.89 |
| Gross Margin | 72.37% |
| Net Profit Margin | 14.72% |
| Debt/Equity Ratio | -157.9% |
How did BTMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 22:42 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
biote Corp. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Kaumil Gajrawala | Jefferies LLC |
| George Kelly | Roth Capital Partners |